Swiss National Bank Buys Shares of 147,400 Eyepoint Pharmaceuticals, Inc. $EYPT

Swiss National Bank acquired a new stake in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) during the 1st quarter, Holdings Channel reports. The fund acquired 147,400 shares of the company’s stock, valued at approximately $1,900,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. California State Teachers Retirement System lifted its holdings in shares of Eyepoint Pharmaceuticals by 20.6% in the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after acquiring an additional 794 shares during the last quarter. RWC Asset Management LLP lifted its stake in Eyepoint Pharmaceuticals by 6.4% in the 4th quarter. RWC Asset Management LLP now owns 17,235 shares of the company’s stock valued at $315,000 after purchasing an additional 1,040 shares during the last quarter. MCF Advisors LLC boosted its position in Eyepoint Pharmaceuticals by 8.3% in the fourth quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock valued at $273,000 after buying an additional 1,149 shares in the last quarter. Raymond James Financial Inc. grew its stake in shares of Eyepoint Pharmaceuticals by 11.0% during the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after buying an additional 1,177 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Eyepoint Pharmaceuticals by 51.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after buying an additional 1,358 shares in the last quarter. Institutional investors own 99.41% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on EYPT shares. Chardan Capital increased their price target on Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Royal Bank Of Canada dropped their target price on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Stifel Nicolaus assumed coverage on Eyepoint Pharmaceuticals in a research note on Thursday, July 16th. They set a “buy” rating and a $40.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Friday, July 17th. Finally, Guggenheim restated a “buy” rating and set a $68.00 price target on shares of Eyepoint Pharmaceuticals in a report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $43.75.

Eyepoint Pharmaceuticals Stock Up 7.9%

Shares of Eyepoint Pharmaceuticals stock opened at $12.86 on Friday. Eyepoint Pharmaceuticals, Inc. has a twelve month low of $9.40 and a twelve month high of $19.11. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -3.67 and a beta of 1.73. The company’s fifty day moving average is $13.19 and its 200 day moving average is $13.90.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, May 6th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%.The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.35 million. As a group, equities analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -3.3 earnings per share for the current fiscal year.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.